Cargando…

Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA

Objectives. To evaluate the analytical performance of an ELISA for the detection of anti-RNA polymerase III antibody (ARA) and to assess IIF as a method for identifying this antibody. Methods. A commercially available ELISA was used to assess the presence of ARA in sera from 1018 SSc patients. The s...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, J. C., Burlingame, R. W., Webb, T. T., Bunn, C. C.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430219/
https://www.ncbi.nlm.nih.gov/pubmed/18499715
http://dx.doi.org/10.1093/rheumatology/ken201
_version_ 1782156372062765056
author Parker, J. C.
Burlingame, R. W.
Webb, T. T.
Bunn, C. C.
author_facet Parker, J. C.
Burlingame, R. W.
Webb, T. T.
Bunn, C. C.
author_sort Parker, J. C.
collection PubMed
description Objectives. To evaluate the analytical performance of an ELISA for the detection of anti-RNA polymerase III antibody (ARA) and to assess IIF as a method for identifying this antibody. Methods. A commercially available ELISA was used to assess the presence of ARA in sera from 1018 SSc patients. The sera had been divided into sub-populations based on the presence of specific autoantibodies, ANA pattern or the absence of both. Patients with ARA (n = 209) had been identified by characteristic ANA pattern by IIF on HEp-2 cell substrate [and additionally by radio-immunoprecipitation (IP) in 157/209 cases]. The remaining 809 SSc patients acted as a control group. Results. Of 157 patients in whom ARA had been confirmed by IP, 150 were positive by ELISA providing a sensitivity of 96%. In the group where ARA had only been assessed by IIF, 100% (52/52) were ELISA positive. The ANA patterns indicating the presence of ARA were a fine-speckled nucleoplasmic stain with additional occasional bright dots, with or without concurrent punctate nucleolar staining. In the SSc control group, the ELISA attained a specificity of 98%, ARA being detected in 17/809 patients. Conclusions. We report the outcome of a study on a large population of SSc patients that shows the ARA ELISA to be of high analytical sensitivity and specificity. We confirm that there is minimal overlap between ARA and other SSc-specific autoantibodies. Additionally, it is demonstrated that the presence of ARA correlates with identifiable patterns by IIF on HEp-2 cell substrate.
format Text
id pubmed-2430219
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-24302192009-02-25 Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA Parker, J. C. Burlingame, R. W. Webb, T. T. Bunn, C. C. Rheumatology (Oxford) Basic Science Objectives. To evaluate the analytical performance of an ELISA for the detection of anti-RNA polymerase III antibody (ARA) and to assess IIF as a method for identifying this antibody. Methods. A commercially available ELISA was used to assess the presence of ARA in sera from 1018 SSc patients. The sera had been divided into sub-populations based on the presence of specific autoantibodies, ANA pattern or the absence of both. Patients with ARA (n = 209) had been identified by characteristic ANA pattern by IIF on HEp-2 cell substrate [and additionally by radio-immunoprecipitation (IP) in 157/209 cases]. The remaining 809 SSc patients acted as a control group. Results. Of 157 patients in whom ARA had been confirmed by IP, 150 were positive by ELISA providing a sensitivity of 96%. In the group where ARA had only been assessed by IIF, 100% (52/52) were ELISA positive. The ANA patterns indicating the presence of ARA were a fine-speckled nucleoplasmic stain with additional occasional bright dots, with or without concurrent punctate nucleolar staining. In the SSc control group, the ELISA attained a specificity of 98%, ARA being detected in 17/809 patients. Conclusions. We report the outcome of a study on a large population of SSc patients that shows the ARA ELISA to be of high analytical sensitivity and specificity. We confirm that there is minimal overlap between ARA and other SSc-specific autoantibodies. Additionally, it is demonstrated that the presence of ARA correlates with identifiable patterns by IIF on HEp-2 cell substrate. Oxford University Press 2008-07 2008-05-22 /pmc/articles/PMC2430219/ /pubmed/18499715 http://dx.doi.org/10.1093/rheumatology/ken201 Text en © 2008 The Author(s) http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic Science
Parker, J. C.
Burlingame, R. W.
Webb, T. T.
Bunn, C. C.
Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
title Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
title_full Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
title_fullStr Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
title_full_unstemmed Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
title_short Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA
title_sort anti-rna polymerase iii antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and elisa
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430219/
https://www.ncbi.nlm.nih.gov/pubmed/18499715
http://dx.doi.org/10.1093/rheumatology/ken201
work_keys_str_mv AT parkerjc antirnapolymeraseiiiantibodiesinpatientswithsystemicsclerosisdetectedbyindirectimmunofluorescenceandelisa
AT burlingamerw antirnapolymeraseiiiantibodiesinpatientswithsystemicsclerosisdetectedbyindirectimmunofluorescenceandelisa
AT webbtt antirnapolymeraseiiiantibodiesinpatientswithsystemicsclerosisdetectedbyindirectimmunofluorescenceandelisa
AT bunncc antirnapolymeraseiiiantibodiesinpatientswithsystemicsclerosisdetectedbyindirectimmunofluorescenceandelisa